Results 151 to 160 of about 21,951 (195)

Management of acute promyelocytic leukemia

Current Oncology Reports, 2002
Acute promyelocytic leukemia (APL) has become the most potentially curable subtype of acute myeloid leukemia (AML) in adults. With current treatment strategies that incorporate all-trans retinoic acid (ATRA), long-term disease-free survival and potential cure rates of 70% to 80% can be expected.
Martin S, Tallman, Chadi, Nabhan
openaire   +2 more sources

Acute Promyelocytic Leukemia: A Perspective

Clinical Lymphoma Myeloma and Leukemia, 2017
Treatment of patients with acute promyelocytic leukemia has significantly improved with the introduction of target specific agents all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) with long term survival a reality for the majority of patients.
Farhad Ravandi, Richard Stone
openaire   +2 more sources

The biology of acute promyelocytic leukemia

Current Oncology Reports, 2001
Acute promyelocytic leukemia (APL) is a disease associated with fusion oncoproteins invariably involving the retinoic acid receptor (Raralpha). Retinoic acid induces differentiation in APL cells and is successfully used in conjunction with chemotherapy to treat and cure a significant percentage of patients with APL.
K K, Mann, W, Shao, W H, Miller
openaire   +2 more sources

Coagulopathy of Acute Promyelocytic Leukemia

Acta Haematologica, 2001
Life-threatening bleeding is frequent in acute leukemias, particularly in acute promyelocytic leukemia (APL), a distinct subtype of acute myelogenous leukemia, characterized by the balanced reciprocal translocation between chromosomes 15 and 17.
A, Falanga, T, Barbui
openaire   +2 more sources

Acute promyelocytic leukemia in childhood

Current Oncology Reports, 2009
Acute promyelocytic leukemia (APL) is a relatively rare form of acute myelogenous leukemia (AML). In the United States, APL in children constitutes only 5% to 10% of AML. Molecularly, the disease is characterized by a fusion protein, promyelocytic leukemia (PML)-retinoic acid receptor (RAR)-alpha that results from a balanced reciprocal translocation ...
John, Gregory, James, Feusner
openaire   +2 more sources

Acute promyelocytic leukemia

Current Treatment Options in Oncology, 2000
The treatment of acute promyelocytic leukemia (APL) is different from other subtypes of acute myelocytic leukemia (AML). All trans-retinoic acid (ATRA) is an essential component of the standard remission induction for all newly diagnosed APL patients. Remission induction with ATRA and chemotherapy given concurrently appears to be associated with fewer ...
openaire   +2 more sources

Acute promyelocytic leukemia in children

Medical and Pediatric Oncology, 1981
AbstractSixteen children (ages 2–17) with acute promyelocytic leukemia (APL) were studied retrospectively. Diagnosis was based on clinical features and morphological criteria of the FAB classification. Bleeding diathesis was the predominant presenting symptom (>85%), associated with laboratory findings of disseminated intravascular coagulation (DIC).
K W, Chan, P G, Steinherz, D R, Miller
openaire   +2 more sources

Acute promyelocytic leukemia and pregnancy

European Journal of Haematology, 2000
Abstract: In acute promyelocytic leukemia (APL), the use of all‐trans‐retinoic acid (ATRA) as a differentiating agent induces complete remission in a high percentage of patients. In pregnancy, however, this drug bears the risk of severe teratogenicity to the child. We report the case of a 23‐yr‐old woman at 21 weeks' gestation suffering from APL.
A A, Giagounidis, M W, Beckmann, A S, Giagounidis, M, Aivado, T, Emde, U, Germing, T, Riehs, A, Heyll, C, Aul   +8 more
openaire   +2 more sources

History of Acute Promyelocytic Leukemia

2017
Within a 60-year time span, the most severe acute leukemia—termed acute promyelocytic leukemia (APL) by the Norwegian author Leif Hillestad—was identified, characterized, and cured. The determination of a precise molecular definition of the genetic defect and the emergence of an antidogmatic paradigm have made the history of APL a model for the ...
openaire   +2 more sources

Acute promyelocytic leukemia

Best Practice & Research Clinical Haematology, 2014
Acute promyelocytic leukemia (APL) is designated M3 in the French-American-British (FAB) classification. Because of its unique clinical features and unique response to certain differentiation-inducing agents, and because of our advanced understanding of the molecular biology and treatment of this leukemia, APL deserves to be presented and discussed in ...
openaire   +1 more source